Reumatologia/Rheumatology - open access journal

The latest issue of Reumatologia is now available.
🔗https://reu.termedia.pl/
Explore the newest research, clinical updates, and expert perspectives in

🌍 May 2 — World Axial Spondyloarthritis Day
Reumatologia journal stands in solidarity with everyone living with AxSpA.
📖 Read our Open Access articles on AxSpA—free to access and share https://reu.termedia.pl/Search/?s=spondyloarthritis
This year’s theme, “Not Only Back Pain,” reminds us that AxSpA is more than just back pain.
The campaign continues, with orange shoelaces symbolizing everyday challenges, alongside the call to “Walk with me.”
Early diagnosis and proper treatment can greatly improve quality of life.

🔬 Nailfold in
Capillaroscopy is becoming an essential, non-invasive tool not only in systemic sclerosis, but also across the broader spectrum of connective tissue diseases.
This review https://doi.org/10.5114/reum/211212 highlights its role in:
✅diagnosis
✅disease monitoring
✅potential support in therapeutic decision-making
📸 The attached images illustrate typical capillaroscopic patterns and underline the importance of standardized interpretation.

🔥A concise and practical guide for clinicians navigating complex eosinophilic disorders
👉 🔗https://doi.org/10.5114/reum/214426
📖 “Eosinophilic granulomatosis with polyangiitis across the eosinophilic spectrum” explores pathogenesis, differential diagnosis, and modern targeted therapies—highlighting the key role of the IL-5/eosinophil axis and personalized treatment approaches.

🔥If you haven’t yet explored the latest issue of Reumatologia, we invite you to take a look.
📖 Discover the newest research and insights in
🔗https://reu.termedia.pl/

🌿 Happy Easter from the Reumatologia Editorial Team! 🐣

We warmly wish our readers, reviewers, authors, and editorial board members a joyful and peaceful Easter. May this special time bring renewal, hope, and inspiration to you and your loved ones. 🌸

With gratitude for your continued support and collaboration.

📢 Editorial Highlight
Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges:
🔗https://doi.org/10.5114/reum/218349
✅Over 50% of patients with giant cell arteritis relapse during glucocorticoid tapering.
✅JAK inhibitors, particularly upadacitinib, are emerging as promising glucocorticoid-sparing therapies.
✅In the SELECT-GCA trial, sustained remission at week 52 was higher with upadacitinib 15 mg (46.4%) vs placebo (29.0%).

🔥The latest issue of Reumatologia is now available!
🔗https://reu.termedia.pl/
✅Giant cell arteritis and the potential role of JAK inhibitors
✅Rituximab treatment in rheumatoid arthritis
✅Zumba Gold as a strategy to improve balance and reduce falls in older adults
✅EGPA across the eosinophilic spectrum: from molecular mechanisms to practical differential diagnosis and targeted therapy

And much more!!

🟣 February 2 – Rheumatoid Arthritis Awareness Day
📖 On RA Awareness Day, Reumatologia invites you to explore our articles on rheumatoid arthritis—covering modern treatment strategies, disease mechanisms, and clinical practice.
🔗https://reu.termedia.pl/Search/?s=rheumatoid+arthritis

🟣 RA is more than a diagnosis. It’s a story we can change!!

Early diagnosis matters. Awareness matters. Science matters.

📢 New editorial in Reumatologia
📝 in – ongoing debate about dosage and route of administration
by Prof. Brygida Kwiatkowska, Polish National Consultant in Rheumatology
🔗https://doi.org/10.5114/reum/215662
🔑 Key takeaways:
✅early diagnosis & rapid MTX dose escalation
✅optimal dosing 20–25 mg/week
✅clear benefits of subcutaneous MTX over oral route
✅better disease control, fewer biologics, improved safety

🧠 Editorial by Prof. Maria Maślińska
Editor-in-Chief of Reumatologia | Member of the EULAR Education Working Group
🔗https://reu.termedia.pl/EULAR-and-Education,216267,0,2.html

This editorial highlights how EULAR is shaping modern education in Europe — through harmonised standards, digital learning, virtual clinical simulations and a strong focus on undergraduate education to attract the next generation of rheumatologists.

Education today. Rheumatology tomorrow.